Viyash Scientific Q4 profit jumps as FY26 revenue rises

Key takeaway from the March-quarter results

Viyash Scientific Limited, formerly known as Sequent Scientific, reported a sharp turnaround in profitability for the quarter ended March 31, 2026. The company announced audited standalone and consolidated financial results for Q4 FY26 and the full year FY26. On a consolidated basis, Viyash posted a net profit of ₹52.11 crore for the March quarter, reversing a net loss of ₹26.24 crore in the year-ago period. Revenue from operations for the quarter stood at ₹920 crore, up from ₹770 crore in Q4 FY25. The results also reflected stronger operating metrics, with the company reporting margin expansion and improved leverage indicators.

What Viyash reported for Q4 FY26

For Q4 FY26, Viyash Scientific’s consolidated revenue from operations came in at ₹920 crore. The company also reported another revenue figure for the quarter at ₹935.88 crore, compared to ₹782.53 crore a year ago. Consolidated net profit for the quarter was ₹52.11 crore versus a net loss of ₹26.24 crore in Q4 FY25. EBITDA for the quarter rose to ₹200.10 crore, and the EBITDA margin expanded by 590 basis points to 21.7%. Gross margin for the quarter improved to 55.1% from 52.8% in Q4 FY25.

On the standalone side, the company reported net profit of ₹66.4 crore for Q4 FY26, compared with a net loss of ₹32.2 crore in Q4 FY25. Standalone earnings before tax (EBT) was ₹125.2 crore for the quarter, compared with a loss of ₹36.7 crore in the prior-year quarter. Basic earnings per share (EPS) for the quarter was reported at 1.2, with diluted EPS at 1.17.

Full-year FY26 performance: revenue and profit trend

For the financial year 2025-26, Viyash Scientific reported revenue from operations of ₹3,420.31 crore, compared to ₹3,006.84 crore in FY25. The company also reported a full-year revenue figure of ₹3,463.86 crore, compared to ₹3,039.73 crore a year ago. Consolidated net income for FY26 stood at ₹177.28 crore, up from ₹23.22 crore in FY25.

On a standalone basis, Viyash reported net profit of ₹224.60 crore for FY26, compared with ₹15.8 crore in FY25. For the full year, basic EPS from continuing operations was 4.09, compared with 0.54 a year ago, while diluted EPS was 4.01 versus 0.53. Annual EBITDA was reported at ₹702.5 crore, with an EBITDA margin of 20.5%, an improvement of 590 basis points year-on-year. Gross margin for the year was reported at 54.3%.

Operational factors highlighted by the company

Alongside the financial performance, Viyash Scientific said it delivered improved results by successfully integrating its plants and operations. The company attributed the improved profitability in the period to strong revenue growth and operational efficiency improvements. The combination of higher scale and better cost control showed up in the quarter’s EBITDA and margin profile.

The March-quarter metrics indicate that profitability improved across both consolidated and standalone results. The company’s reported data points for gross margin and EBITDA margin also suggest a more efficient operating structure compared with the year-ago quarter.

Balance sheet indicator: net debt ratio

Viyash Scientific also reported improvement in its net debt metrics. The Net Debt to LTM EBITDA ratio reduced to 0.2x from 1.0x in FY25. While the company did not detail the drivers behind the movement in the ratio in the provided results summary, the reported reduction points to a stronger leverage position compared to the previous year.

Stock and identifiers investors track

Viyash Scientific trades under NSE: VIYASH and BSE: 512529, and is classified under Healthcare, with industry listed as Pharmaceuticals and Drugs. On 19 May 2026, the stock opened at ₹228.02, with a previous close of ₹225.48. The share price was also cited at ₹228.73 at 15:58 on 19 May 2026, and another cited price point in the same context was ₹229.45. The company’s market capitalisation was stated as ₹10,024.107819765 crore.

Financial snapshot table (all figures in ₹ crore)

Market impact: what changed in the reported numbers

The most visible change in Viyash Scientific’s Q4 FY26 print was the move from losses to profits on both standalone and consolidated bases. Revenue from operations for the quarter increased from ₹770 crore in Q4 FY25 to ₹920 crore in Q4 FY26. The company also reported EBITDA margin expansion of 590 basis points in the quarter, alongside higher gross margin.

For the full year, revenue from operations rose to ₹3,420.31 crore from ₹3,006.84 crore, while consolidated net income increased to ₹177.28 crore from ₹23.22 crore. Standalone net profit growth was also sharp, rising to ₹224.60 crore from ₹15.8 crore. These reported numbers, along with a lower Net Debt to LTM EBITDA ratio of 0.2x, provide the key factual markers investors typically evaluate after audited results.

Analysis: why this quarter matters for investors

The reported results show that Viyash Scientific combined higher quarterly revenue with stronger profitability, as reflected in both net profit and margins. A 590-basis-point improvement in EBITDA margin to 21.7% is a meaningful operational shift when paired with higher revenue from operations. The gross margin improvement to 55.1% in Q4 FY26 from 52.8% in Q4 FY25 adds another data point supporting improved operating performance.

At the balance-sheet level, the reduction in Net Debt to LTM EBITDA to 0.2x from 1.0x in FY25 is a notable change in leverage metrics. Alongside the company’s statement on plant and operations integration, these numbers form the core of what the March-quarter and FY26 results communicated.

Conclusion

Viyash Scientific’s audited FY26 results show a turnaround in Q4 profitability, higher revenue, and expanded margins compared with the prior year. The company also pointed to successful integration of plants and operations as a factor behind improved performance. Investors will continue to track subsequent disclosures and quarterly updates following the audited year-end print for the period ended March 31, 2026.